BlaidsX Neuro vs Lexie B3

The BlaidsX Neuro is a mid-priced OTC hearing aid that earns a B grade with a SoundScore of 3.3/5 in our lab testing. At $799 for this behind-the-ear, rechargeable device, it sits in a competitive price bracket where several higher-performing alternatives exist. In our testing, the Neuro shows a mixed performance profile. Its standout strength is speech clarity in quiet environments, scoring 3.3/5—a solid result that's 0.54 points above the OTC category average. Feedback handling is excellent at 5.0/5, meaning users can expect stable performance without whistling or squealing during normal use. However, the device struggles in more challenging areas: speech in noise scores just 1.0/5 (0.48 points below category average), and music streaming registers at 0.0/5, significantly below the already-modest category average. Own-voice comfort is another weak point, scoring 1.7/5—well below the category average by 0.81 points. This may result in an unnatural sound of one's own voice during conversations. The tuned fit improves the overall score modestly from 3.3 to 3.5, primarily through enhanced feedback stability, though own-voice comfort decreases with the more occluding tulip dome coupling. The BlaidsX Neuro may suit users who primarily need help hearing speech in quieter settings and prioritize feedback-free performance. However, those who frequently encounter noisy environments, stream music, or have higher expectations for overall sound quality should consider alternatives in this price range, several of which score substantially higher in our testing.

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.